Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients

Clinical Transplantation

Volumn 24, Issue 4, 2010, Pages

  Tedesco Silva, Helio ^a   Felipe, Claudia R ^a   Park, Sung I ^a   Pinheiro Machado, Paula G ^a   Garcia, Riberto ^a   Slade, Alan ^b   Schmouder, Robert ^b   Medina Pestana, Jose O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Enteric coated mycophenolate sodium; Mycophenolate mofetil; Mycophenolic acid; Predose level; Renal transplantation; Variability

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE PYELONEPHRITIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955732873     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01183.x     Document Type: Article

References (38)

1. Meier-Kriesche HU, Li S, Gruessner RW. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006, 6:1111.
2. Budde K, Glander P, Diekmann F. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004, 5:1333.
3. Arns W, Breuer S, Choudhury S. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005, 19:199.
4. Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006, 81:1290.
5. Bolin P, Tanriover B, Zibari GB. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007, 84:1443.
6. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006, 82:1413.
7. Budde K, Bauer S, Hambach P. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007, 7:888.
8. Budde K, Curtis J, Knoll G. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004, 4:237.
9. Salvadori M, Holzer H, de Mattos A. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004, 4:231.
10. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 1991, 20:477.
11. Pietruck F, Budde K, Salvadori M. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clin Transplant 2007, 21:117.
12. Van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transplant 2005, 5:199.
13. Kaplan B. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Curr Med Res Opin 2006, 22:2355.
14. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001, 23:305.
15. Tredger JM, Brown NW. Mycophenolate: better value through monitoring? Transplantation 2006, 81:507.
16. Van Gelder T, Hilbrands LB, Vanrenterghem Y. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999, 68:261.
17. Le Meur Y, Büchler M, Thierry A. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007, 7:2496.
18. Flechner SM, Feng J, Mastroianni B. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005, 79:926.
19. Borrows R, Chusney G, Loucaidou M. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006, 6:121.
20. Van Gelder T, Le Meur Y, Shaw LM. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006, 28:145.
21. Budde K, Tedesco-Silva H, Pestana JM. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monit 2007, 29:381.
22. Tedesco-Silva H, Bastien MC, Choi L. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc 2005, 37:852.
23. Gummert JF, Christians U, Barten M, Silva H, Morris RE. High-performance liquid chromatographic assay with a simple extraction procedure for sensitive quantification of mycophenolic acid in rat and human plasma. J Chromatogr B Biomed Sci Appl 1999, 721:321.
24. Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SD, Struchiner C. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 2007, 8:1299.
25. Shah VP, Yacobi A, Barr WH. Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res 1996, 13:1590.
26. Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther 2005, 43:485.
27. Hummel M, Yonan N, Ross H. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant 2007, 21:18.
28. Budde K, Glander P, Krämer BK. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 2007, 83:417.
29. Van Hest RM, Mathot RA, Vulto AG. Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view. Ther Drug Monit 2006, 28:31.
30. Shum B, Duffull SB, Taylor PJ, Tett SE. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 2003, 56:188.
31. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13.
32. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005, 78:317.
33. Arns W, Cibrik DM, Walker RG. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006, 82:1004.
34. Gaston RS, Kaplan B, Shah T. Fixed- or Concentration-Dose Mycophenolate Mofetil with Standard- or Reduced-Dose Calcineurin Inhibitors: the OptiCept trial. Am J Transplant 2009, 9:1607.
35. van Gelder T, Silva HT, de Fijter JW. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008, 86:1043.
36. Le Meur Y, Büchler M, Thierry A. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007, 7:2496.
37. Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996, 41:513.
38. Myfortic: Prescribing Information [online] http://www.pharma.us.novartis.com/product/pi/pdf/myfortic.pdf, Available from URL: [accessed on July 28, 2009]